THORChain released an update on the hacking incident on platform X. Preliminary evidence suggests that a node that recently joined the network may have been controlled by a malicious operator, who exploited the GG20 TSS vulnerability to obtain key information from vault participants, ultimately reconstructing the vault private key and executing unauthorized withdrawal transactions. Currently, multiple THORChain nodes have been shut down, resulting in the network being in a paused state. RUNE transfers are expected to resume in about 12 hours, but the specific situation will depend on node decisions. Functions such as trading, liquidity provider operations, and signing are still unavailable, and a full restoration of network functionality is expected to take several days. Recovery plans are under discussion and may include reducing the staking of affected nodes, as well as other remedial measures proposed by the community.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.



Key Takeaways Sky co-founder Rune Christensen has leveraged strategic moves to short the S&P 500 and invest in…

Key Takeaways: The attacker moved $175 million in stolen ETH to new wallets using privacy tools. The exploit…






Key Takeaways: The Kelp DAO exploiter has moved $175 million worth of Ether, part of a larger $290…







Latest Crypto Market Snapshot as of August 22, 2025 BTC Soars to $115,250.00 ETH Hits $4,450.75 XRP Climbs…

Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.












Key Takeaways Sky co-founder Rune Christensen has leveraged strategic moves to short the S&P 500 and invest in…
Key Takeaways: The attacker moved $175 million in stolen ETH to new wallets using privacy tools. The exploit…